Targeted therapy and handfoot skin reaction in advanced renal cell carcinoma

Expert Opinion on Drug Safety

Volumn 9, Issue 3, 2010, Pages 459-470

  Yang, Chih Hsun ^a   Chuang, Cheng Keng ^a   Hsieh, Jia Juan ^a   Chang, John Wen Cheng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Handfoot skin reaction; Renal cell carcinoma; Targeted therapy; Tolerance

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BIOLOGICAL MARKER; CYTARABINE; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; INTERLEUKIN 2; LACTIC ACID PLUS SALICYLIC ACID; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASIAN; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYROID DISEASE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG DELIVERY SYSTEM; FOOT; HAND; KIDNEY TUMOR; METHODOLOGY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; FOOT; HAND; HUMANS; KIDNEY NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES;

EID: 77951641229     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003596349     Document Type: Review

References (79)

1. Garcia M Jemal A Ward EM et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society 2007
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58(2):71-96
3. Godley PA, Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001;13(3):199-203
4. Ravaud A, Wallerand H, Culine S, et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008;54(2):315-325
5. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22(1):42-60
6. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 1983;10(4):422-430
7. Papac RJ, Keohane MF. Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen. Eur J Cancer 1993;29A(7):997-999
8. Gouttefangeas C, Stenzl A, Stevanovic S, et al. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 2007;56(1):117-128
9. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005(1):CD001425
10. Linehan WM, Zbar B, Klausner R. Renal carcinoma. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. 2001. p. 907-929
11. Linehan WM, Zbar B, Klausner R. Renal Carcinoma. In: Vogelstein B, Kinzler K, editors. 2002
12. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. Jama 1995;273(7):564-570
13. Clifford SC, Maher ER. Von Hippel-Lindau disease: clinical and molecular perspectives. Adv Cancer Res 2001;82:85-105
14. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997;76(6):381-391
15. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2(9):673-682
16. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004;93(3):297-302
17. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10
18. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3(5):391-400
19. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42(18):3127-3139
20. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7(10):3129-3140
21. Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol 2008;144(11):1525-1526
22. Rutkowski P, Symonides M, Zdzienicki M, et al. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov 2008;3(2):88-99
23. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-337
24. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-972
25. Hanna SC, Heathcote SA, Kim WY. mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther 2008;8(2):283-292
26. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158(3):592-596
27. de Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45(5):765-773
28. Network NCC. Kidney Cancer Version 2. Clinical practice guidelines in oncology 2009. Available from: http://www.nccn. org/professionals/physician-gls/ PDF/kidney.pdf (Accessed Dec 2009)
29. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-124
30. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 2009;27(22):3584-3590
31. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-2281 (Pubitemid 46849157)
32. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26(2):202-209
33. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-434
34. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-2111
35. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422-5428
36. Rini BI, Halabi S, Rosenberg J. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. ASCO Annual Meeting Proceedings. J Clin Oncol 2009;27(18S):abstract. LBA5019
37. Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings. J Clin Oncol 2009;27:abstract 5020
38. Rini BI, Halabi S, Rosenberg J. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma. 2008 ASCO Annual Meeting Proceedings; Genitourinary Cancer Symposium: abstract 350
39. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-1289
40. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-134
41. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):abstract 5023
42. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-2512 (Pubitemid 46630627)
43. Knox JJ, Figlin RA, Stadler WM, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and effecacy. ASCO Annual Meeting Proceedings. J Clin Oncol 2007 Clin Sci Symp 2007;25(18S):abstract 5011
44. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-456
45. Kay A, Motzer RJ, Figlin R, et al. Update data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings. Genitourin Cancers Symp 2009:abstract
46. Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?& vmview=abst-detail-view& confID=64&abstractID=20488. (Last accessed 23 Dec 2009)
47. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178(5):1883-1887
48. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded open access trial with subpopulation analysis. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol Clin Sci Symp 2007;25(18S):abstract 5010
49. Gore ME, Szczylik C, Porta C, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded open access trial with subpopulation analysis. Eur J Cancer Suppl 2007;5(4):abstract 4503
50. Votrient[package-list]. Research Triangle Park, NC: GlaxoSmithKline; 2009
51. Sternberg CN. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 27, 2009 ASCO Annual Meeting Proceedings 2009; Session: Genitourinary Cancer (Testes, Kidney, and Bladder) (Oral Presentation)
52. Sternberg CN, Szczylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings. J Clin Oncol 2009;27:abstract 5021
53. Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009;35(3):297-307
54. Porta C, Szczylik C, Bracarda S, et al. Short-and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:abstract 5114
55. Hutson TE. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. Expert Rev Anticancer Ther 2007;7(9):1193-1202
56. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-918
57. Choueiri TK, Vaziri SA, Rini BI, et al. Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings, Clinical Science Symposium. J Clin Oncol 2007;25(18S):abstract 5012
58. Wolter P, Stefan C, Decallonne B. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:abstract 5126
59. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006;42(4):548-556
60. Hong M, Jeung H, Chung H. Predictive factors associated with clinical outcome and safety in Korean patients with metastatic renal cell carcinoma treated with sunitinib. ASCO Annual Meeting Proceedings. J Clin Oncol 2009;27:abstract e16111
61. Kim JJ, Vaziri SA, Elson P. VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients. ASCO Annual Meeting Proceedings. J Clin Oncol 2009;27(15S):abstract 5005
62. Erp N, Mathijssen RH, Veldt AA. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. ASCO Annual Meeting Proceedings. J Clin Oncol 2009;27(15S):abstract 5006
63. van der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99(2):259-265
64. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15(4):1411-1416
65. Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009;14(3):291-302
66. Akaza H, Tsukamoto T, Murai M, et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37(10):755-762
67. Janusch M, Fischer M, Marsch W, et al. The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006;16(5):494-499
68. Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19(8):1387-1392
69. Harshman L, Srinivas S. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. Onkologie 2008;31(8-9):432-433
70. George S, Blay JY, Casali PG, et al. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis. ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:abstract 10554
71. Srinivas S, Roigas J, Gillessen S, et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): updated results. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):abstract 5040
72. Pfizer. Sunitinib malate schedule 4/2 vs sunitinib malate continuous dosing as first-line therapy for metastatic renal cell cancer (RCC). NCT00267748
73. Houk BE, Bello CL, Michaelson MD, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/ pharmacodynamic (PKPD) approach. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):abstract 5027
74. Escudier B, Srinivas S, Roigas J, et al. A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC)-final results. Eur J Cancer Suppl, Abstract Book 2007;5(4):abstract 4504
75. Motzer RJ. Highlights from ASCO and ECCO 2007: update on targeted treatment of metastatic renal cell carcinoma. Cancer Therapy 2008;6:425-438
76. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
77. Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13(10):1084-1096
78. McDermott DF. The application of high-dose interleukin-2 for metastatic renal cell carcinoma. Med. Oncol 2009;26(Suppl 1):13-17
79. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009;32(2):181-185